Medication Management
Antidepressants and Teens: The Boxed Warning Explained
By Dr. Stacey Forbes, DNP, APRN, PMHNP-BC · Updated October 12, 2026
Key Takeaways
- In October 2004 the FDA directed manufacturers to add a boxed warning that antidepressants increased suicidal thoughts and behaviors in children and adolescents in short-term trials; the warning now covers patients through age 24.
- The trials showed more suicidal thinking and behavior on medication than on placebo, but no completed suicides occurred in the pediatric trials reviewed.
- Whether the warning has done more good than harm is still debated: some studies link it to less treatment and more suicide attempts, while other researchers argue that evidence is weak.
- Fluoxetine and escitalopram are FDA-approved for adolescent depression; the practical message is close monitoring in the first months, not avoiding treatment.
Every antidepressant sold in the United States carries a black-bordered “boxed” warning about suicidal thoughts in young people. For parents it can be the scariest line on the pharmacy printout. The warning is real and worth understanding, but it says something narrower than many people assume. This guide explains where it came from, what the data actually showed, why experts still argue about its effects, and how to use it as a monitoring plan rather than a reason to avoid treatment.
Where the warning came from
In the early 2000s the FDA reanalyzed placebo-controlled trials of antidepressants in children and adolescents. According to an account of the FDA’s deliberations published in Pediatrics in 2005, the agency pooled 24 trials and found that young people assigned to an antidepressant had about twice the rate of possible or definite suicidality events as those on placebo. On October 15, 2004, the FDA directed manufacturers to add a boxed warning about this risk to all antidepressants.
The warning was later widened. Current labels state that antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents and young adults in short-term studies, and the analysis behind it covers patients aged 24 and younger.
What the data actually showed
The current labels summarize pooled placebo-controlled trials involving about 4,500 pediatric and 77,000 adult patients. The numbers are worth seeing directly:
| Age group | Difference vs placebo in suicidal thoughts and behaviors, per 1,000 patients treated |
|---|---|
| Under 18 | 14 additional patients |
| 18 to 24 | 5 additional patients |
| 25 to 64 | 1 fewer patient |
| 65 and older | 6 fewer patients |
Three details are often lost. First, the outcome was suicidal thinking and behavior as reported in trials, not deaths: the FDA review summarized in Pediatrics notes there were no completed suicides in the 24 pediatric studies. Second, these were short-term trials, and the labels state it is unknown whether the risk extends beyond about four months. Third, the labels also note that depression itself is a major risk factor for suicide, and that antidepressants delay the return of depression in adults.
So the warning describes a real, measurable signal of increased suicidal thinking in a minority of young people early in treatment. It does not show that antidepressants cause teen suicides, and it does not say they should not be used.
The debate: did the warning help or hurt?
After the warnings and the heavy media coverage around them, antidepressant prescribing to young people dropped. What happened next is contested, and both sides deserve a hearing.
The case that it caused harm. A 2014 study in the BMJ by Lu and colleagues used insurance data from 11 U.S. health plans. In the second year after the warnings, antidepressant use fell by 31% among adolescents and 24% among young adults, while poisonings with psychotropic drugs, used as a stand-in for suicide attempts, rose by about 22% and 34%. Completed suicides did not change. The authors concluded that warnings and media coverage can have unintended consequences that need to be monitored.
The case that the evidence is weak. In a 2020 review in Frontiers in Psychiatry, Spielmans and colleagues argued that the population-level studies linking the warning to harm are methodologically weak, that psychotropic poisonings are a questionable proxy for suicide attempts, and that the trial data supporting the warning remain sound. They also noted that prescribing later recovered.
Where does that leave a family? Both camps agree on the practical middle ground: depression in teens is serious and treatable, medication can help, and the first weeks and months on any antidepressant call for closer attention.
Which antidepressants are FDA-approved for young people
Many antidepressants are prescribed to teens “off-label,” which is legal and sometimes appropriate. A few have FDA approval for pediatric use based on trials in young people:
| Medication | Pediatric approval on the current label |
|---|---|
| Fluoxetine (Prozac) | Major depression (efficacy shown in ages 8 to 18); OCD from age 7 — label |
| Escitalopram (Lexapro) | Major depression from age 12; generalized anxiety disorder from age 7 — label |
| Duloxetine (Cymbalta and generics) | Generalized anxiety disorder from age 7 — label |
Approval does not mean other choices are wrong, and every one of these carries the same boxed warning. Medication is also rarely the whole plan; therapy, sleep, activity and school and family supports matter at least as much. Our guide to signs of depression in teens covers what to look for in the first place.
Monitoring in the first months
The labels instruct prescribers to monitor everyone starting an antidepressant for worsening and for new suicidal thoughts, especially during the first few months and whenever the dose changes, and to counsel families to watch for changes and report them. In practice that usually means more frequent check-ins at the start, including by telehealth, and a clear way for the teen and parents to reach the prescriber between visits.
Good monitoring also means asking directly. Asking a teenager whether they are having thoughts of suicide does not plant the idea; it opens a door. A written safety plan, made before anything goes wrong, lists warning signs, coping steps, people to call and how to make the home safer, including locking up medications and firearms.
What parents should watch for
Watch especially for changes that are new or clearly worse since the medication started or the dose changed:
- talk of death, suicide, hopelessness or being a burden
- new or worse agitation, restlessness, irritability, anger or aggression
- acting on dangerous impulses, or an unusual burst of energy and talkativeness with little sleep
- panic attacks or severe new anxiety
- pulling away from friends and family or giving away possessions
- marked changes in sleep
Act today if…
- your teen talks about wanting to die or has a plan: call or text 988, or call 911 if they are in immediate danger
- you notice sudden agitation, aggression or reckless behavior after starting or changing a medication: call the prescriber the same day
Do not stop the medication abruptly on your own; call the prescriber, who can advise safely.
If you are not sure whether what you are seeing is serious, our guide on when to seek psychiatric help for your teen sorts emergencies from things that can wait for an appointment.
Consent rules depend on the state
Who can agree to a teen’s psychiatric medication is set by state law, and the differences are large. In New Mexico, a teen aged 14 or older can consent to some mental health treatment, including medication; in Florida, a parent must consent to any psychiatric medication for a minor. Our state guides explain the details:
- Texas teen mental health consent
- New Mexico: what changes at 14
- Florida teen mental health consent
- Arizona parental consent rules
- Colorado: therapy at 12, services at 15
Whatever the law allows, treatment usually goes best when a parent or trusted adult is involved in monitoring, because they see changes the teen may not report.
How Willow & Stone approaches antidepressants for teens
Willow & Stone provides teen and adolescent psychiatry, and the boxed warning shapes how medication is started. Before prescribing, Dr. Forbes takes a full history with the teen and parent, looks at sleep, substance use and medical contributors such as thyroid or iron, and discusses therapy as part of the plan. When an antidepressant is chosen, it starts at a low dose with closer follow-up early on and a plan the family understands, including who to call. Read more about our integrative approach to medication management.
Common Questions
Do antidepressants cause suicide in teenagers?
The trials behind the FDA warning found more suicidal thoughts and behaviors in young people taking antidepressants than placebo, about 14 additional cases per 1,000 under age 18. They did not show an increase in suicide deaths; no completed suicides occurred in the pediatric trials the FDA reviewed. Untreated depression is itself a major suicide risk, so the warning is a call for close monitoring.
What age does the antidepressant black box warning apply to?
The warning applies to children, adolescents and young adults. The pooled analysis on current labels found increased risk in patients 24 and younger, no increase in adults over 24, and a reduction in people 65 and older. The FDA first required the warning for pediatric patients in October 2004.
Which antidepressant is approved for teens?
For depression, fluoxetine (Prozac) has FDA approval for children and adolescents, with efficacy shown from age 8, and escitalopram (Lexapro) is approved from age 12. Escitalopram and duloxetine are approved for generalized anxiety disorder from age 7. Other antidepressants are sometimes prescribed off-label after a careful discussion.
How long does the increased risk last?
The labels note that the data come from short-term trials and that it is unknown whether the risk extends beyond about four months. Monitoring is most intensive during the first few months and after any dose change, but families should keep communicating with the prescriber throughout treatment.
Can my teen start antidepressants without my consent?
It depends on your state. Florida requires a parent’s consent for any psychiatric medication for a minor, while New Mexico allows teens 14 and older to consent to some treatment, including medication. Texas, Arizona and Colorado each have their own rules. Our state teen-consent guides explain the details.
Part of our medication management guide
Sources & Further Reading
- Leslie et al. — The FDA’s Deliberations on Antidepressant Use in Pediatric Patients (Pediatrics, 2005)
- DailyMed — Lexapro (escitalopram) prescribing information, boxed warning and pediatric use
- DailyMed — Prozac (fluoxetine) prescribing information
- Lu et al. — Changes in antidepressant use by young people and suicidal behavior after FDA warnings (BMJ, 2014)
- Spielmans et al. — Duty to Warn: Antidepressant Black Box Suicidality Warning Is Empirically Justified (Frontiers in Psychiatry, 2020)
- DailyMed — Duloxetine delayed-release capsules prescribing information
This article is general education, not advice for your situation. Do not start, stop, or change a medication or supplement without talking to the clinician who prescribes it.
If you need help right now
Willow & Stone is an outpatient practice and is not an emergency service. If you or someone you care about is in immediate danger, call 911.
For urgent mental health support at any hour, call or text 988 to reach the Suicide & Crisis Lifeline, or text HOME to 741741 for the Crisis Text Line. Both are free, confidential, and available 24/7 nationwide.
Dr. Stacey Forbes, DNP, APRN, PMHNP-BC
Board-certified Psychiatric-Mental Health Nurse Practitioner and founder of Willow & Stone Integrative Mental Health. Nearly two decades of clinical experience; integrative, root-cause psychiatry in person in Arlington and by telehealth. Licensed in Texas, New Mexico, Florida, Alaska, Arizona & Colorado.
About Dr. Forbes →